TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10329871
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered misoprostol
Study: 21644418
Drug: Vaginally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginally administered misoprostol
Study: 2007107
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg hyperbaric bupivacaine
Study: 18070995
Drug: Losartan-based antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan-based antihypertensive therapy
Study: 22070095
Drug: Atenolol-based antihypertensive
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol-based antihypertensive therapy
Study: 15548795
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus 2.5% povidone‐iodine every 2 hours for 2 weeks
Study: 9625084
Drug: Parents as
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parents as agents of change (experimental group)
Study: 9625084
Drug: Children as
Normalized name: AZELASTINE HYDROCHLORIDE 205.5 ug NASAL SPRAY, METERED [Children Astepro Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children as agents of change (control group)
Study: 17212003
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha ‐ 2b (Intron‐A) 3 million units (MU) subcutaneously thrice weekly for 6 months
Study: 21416235
Drug: Ningdong granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ningdong granule (NDG) 5 mg/kg/day
Study: 7851625
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 131I adjusted to the patients' thyroid weight (group 1)
Study: 7851625
Drug: Repeated lower
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated lower dose of 131I (approximately 30Gy) (group 2)
Study: 61564
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of urea, saline, and sodium bicarbonate; oral water load
Study: 31606448
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) 20-min daily stimulation
Study: 31606448
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) 2×20-min daily stimulation
Study: 25823271
Drug: Psychotherapy in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy in addition to medical therapy
Study: 25823271
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy only (Control Group 2)
Study: 15104658
Drug: Granulocyte apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte apheresis (GA-1) after initial mobilization with glycosylated G-CSF 6.0 micro g per kg and oral dexamethasone (DXM, 8 mg)
Study: 15104658
Drug: Remobilization with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remobilization with DXM 8 mg
Study: 15104658
Drug: Remobilization with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remobilization with DXM 4 mg
Study: 15104658
Drug: Remobilization with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remobilization with DXM 1.5 mg
Study: 9781831
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg aspirin/day
Study: 9781831
Drug: Aspirin (30-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (30-300 mg/day)
Study: 17974384
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.25 mcg/day 1‐alpha‐OHD3 plus 10 mcg/day 24,25(OH)2D3
Study: 2681316
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 1.0 mg/kg
Study: 26152411
Drug: Fluralaner (Bravecto)
Normalized name: fluralaner Topical Solution [Bravecto]
DrugBank: Fluralaner (DB11414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluralaner (Bravecto) (dosage 25.1 - 49.4 mg/kg)
Study: 19735513
Drug: High flavanol
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flavanol (HF) chocolate, 20 g daily for 12 weeks
Study: 19735513
Drug: Low flavanol
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flavanol (LF) chocolate, 20 g daily for 12 weeks
Study: 17023228
Drug: Controlled-release carvedilol
Normalized name: carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release carvedilol (CR) 20 mg once daily
Study: 17023228
Drug: Immediate-release carvedilol
Normalized name: carvedilol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release carvedilol (IR) 6.25 mg twice daily
Study: 17023228
Drug: Controlled-release carvedilol
Normalized name: carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release carvedilol (CR) 80 mg once daily
Study: 17023228
Drug: Immediate-release carvedilol
Normalized name: carvedilol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release carvedilol (IR) 25 mg twice daily
Study: 17023228
Drug: Controlled-release carvedilol
Normalized name: carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release carvedilol (CR)
Study: 17023228
Drug: Immediate-release carvedilol
Normalized name: carvedilol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release carvedilol (IR)
Study: 10357953
Drug: recombinant follicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant follicle stimulating hormone (rFSH)
Study: 10357953
Drug: urinary follicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: urinary follicle stimulating hormone (uFSH)
Study: 1904183
Drug: Naproxen 250
Normalized name: naproxen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 250 mg thrice daily for 4 weeks postoperatively
Study: 23486755
Drug: Cognitive-behavioral training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral training and automated phone calls (6 sessions, 90 mins each, weekly; phone calls twice daily for 1 year)
Study: 24429855
Drug: Preoperative antiseptic
Normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative antiseptic treatment of the operative field
Study: 18492760
Drug: Preoperative octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative octreotide treatment (20 mg im every 28th day for 6 months)
Study: 18492760
Drug: Preoperative octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative octreotide treatment (20 mg im every 28th day for 6 months) in patients with macroadenomas
Study: 12975720
Drug: [(14)C]M100240 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: [(14)C]M100240 (25 mg, 50 microCi) as an oral solution under fasting conditions
Study: 27454273
Drug: Intrathecal 10
Normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 10 mg of hyperbaric bupivacaine 0.5% and 5 µg of dexmedetomidine (group I)
Study: 27454273
Drug: Intrathecal 10
Normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 10 mg of hyperbaric bupivacaine 0.5% and 0.1 mg/kg ketamine (group II)
Study: 27454273
Drug: Intrathecal 10
Normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 10 mg of hyperbaric bupivacaine 0.5%, 5 µg of dexmedetomidine, and 0.1 mg/kg of ketamine (group III)
Study: 20088937
Drug: Avidin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avidin (100 mg)
Study: 18397971
Drug: Medication Event
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Medication Event Monitoring System (MEMS) used daily
Study: 16521844
Drug: GEL (1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEL (1.1 +/- 0.2 g/kg body mass carbohydrate)
Study: 16521844
Drug: PLACEBO (flavored
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLACEBO (flavored placebo drink, 426 +/- 227 mL)
Study: 10579151
Drug: Rosiglitazone 8
Normalized name: rosiglitazone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 8 mg orally once daily for 14 days
Study: 10579151
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg oral dose
Study: 8610720
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (500 microgram) + metaproterenol sulfate (15 mg)
Study: 8610720
Drug: Metaproterenol sulfate
Normalized name: Metaproterenol Sulfate
DrugBank: Orciprenaline (DB00816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metaproterenol sulfate (15 mg)
Study: 2998440
Drug: Bread with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread with 10 g bran (raw or baked) and fermentation times of 15 min, 45 min, 3 h, or 16 h
Study: 2998440
Drug: Bread with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread with 16 g bran (raw or baked) and fermentation times of 15 min, 45 min, 3 h, or 16 h
Study: 2998440
Drug: Bread with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread with 30 g bran (raw or baked) and fermentation times of 15 min, 45 min, 3 h, or 16 h
Study: 2998440
Drug: Bread with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread with no bran, but phytate and Zn added equivalent to 10 g bran
Study: 23452436
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ranibizumab with last acuity of drop-outs carried forward
Study: 23452436
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ranibizumab in late phase
Study: 23452436
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ranibizumab in early phase
Study: 20103782
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) - 6 mg/m² every 4 weeks for 3 cycles
Study: 20103782
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - no postremission therapy
Study: 18051017
Drug: Family Focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Focused Grief Therapy
Study: 16191743
Drug: D2 dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2 dopamine receptor TaqI A polymorphism
Study: 11945097
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride 800 mg/day
Study: 1888345
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment (stimulus control/relaxation training)
Study: 30400939
Drug: Weekly high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly high-dose recombinant human erythropoietin (EPO) 40,000 IU/mL for 12 weeks
Study: 30400939
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) infusions for 12 weeks
Study: 24715364
Drug: Clozapine plasma
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine plasma levels (Clz pl≥300μg/L)
Study: 24715364
Drug: Clozapine plasma
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine plasma levels (Clz pl<300μg/L)
Study: 15793941
Drug: Pneumococcal seven-valent
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal seven-valent conjugate vaccine (Prevenar)
Study: 11607795
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg or Enalapril 20 mg (for patients ≤40 years); Amlodipine 10 mg + Atenolol 50 mg or Enalapril 20 mg + Hydrochlorothiazide 25 mg (for patients >40 years)
Study: 9893735
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg twice a day
Study: 9893735
Drug: L-NMMA (0.75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (0.75, 1.5, and 3.0 mg/kg/h)
Study: 8281874
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg four times a day
Study: 7223302
Drug: Albumin therapy
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin therapy (60-75 g postoperatively)
Study: 7223302
Drug: Albumin therapy
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin therapy and Control
Study: 30185291
Drug: Clinical pharmacist
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacist intervention (e.g., medication dose adjustment, initiation, or discontinuation)
Study: 30185291
Drug: Factors predictive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors predictive of requiring an intervention (e.g., clopidogrel dispensing, fall, vertebral fracture diagnosis)
Study: 17660026
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF), 1 g twice daily for 12 months
Study: 17660026
Drug: Cyclophosphamide, 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide, 1.5 mg/kg/d for 12 months
Study: 11799102
Drug: Aliskiren 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 40 mg/d
Study: 11799102
Drug: Aliskiren 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 80 mg/d
Study: 11799102
Drug: Aliskiren 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 160 mg/d
Study: 10320183
Drug: Lidocaine/prilocaine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/prilocaine cream (EMLA; Astra, Sweden) for 1 hour postburn
Study: 10320183
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream for 1 hour postburn
Study: 8542174
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy for colorectal cancer
Study: 1961137
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg midazolam HCl
Study: 31958286
Drug: First-line EGFR
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line EGFR inhibitors
Study: 31073879
Drug: Group-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-Based Cognitive Behavioral Therapy (CBT), 12 sessions
Study: 16266457
Drug: 500 micromol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micromol/L Hcy
Study: 16266457
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid with 500 micromol/L Hcy
Study: 10428146
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg once daily for 12 months
Study: 10428146
Drug: Flutamide 250
Normalized name: flutamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide 250 mg twice daily for 12 months
Study: 2097149
Drug: CAP (C
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP (C = 600 mg/sqm, A = 45 mg/sqm, P = 50 mg/sqm)
Study: 2097149
Drug: CA (C
Normalized name: COFFEA ARABICA (COFFEE) SEED OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA (C = 600 mg/sqm, A = 45 mg/sqm)
Study: 31797578
Drug: Filgotinib 450
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Filgotinib 450 mg
Study: 16041547
Drug: Rifampin 300
Normalized name: rifampin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 300 mg daily (n=6)
Study: 16041547
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg daily (n=6)
Study: 31815653
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course systemic antibiotics (≤ 7 days)
Study: 31815653
Drug: Long course
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long course systemic antibiotics (≥ 4 weeks)
Study: 20701024
Drug: Melatonin 5
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5 mg daily, one hour before sleep (group A)
Study: 20701024
Drug: Melatonin 5
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5 mg daily, one hour before sleep (group B)
Study: 16639731
Drug: FAC (5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC (5-fluorouracil 1000 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2)
Study: 16639731
Drug: FAC followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FAC followed by high-dose chemotherapy (HDCT) with autologous stem cell support (ASCS) (high-dose cyclophosphamide 5250 mg/m2, etoposide 1200 mg/m2, cisplatin 165 mg/m2)
Study: 8908525
Drug: Low-dose combined
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combined oral contraceptive (Group 1, n = 48)
Study: 8908525
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate 100 mg daily for the first 10 days of a 21-day cycle with an oral contraceptive containing 2 mg cyproterone acetate (Group 2, n = 65)
Study: 8908525
Drug: Spironolactone (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (100-200 mg daily) (Group 3, n = 12)
Study: 8908525
Drug: Ketoconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (400 mg daily) (Group 4, n = 16)
Study: 8908525
Drug: Low-dose combined
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combined oral contraceptive (Group 1)
Study: 6761087
Drug: 3-day treatment
Normalized name: Gyne-Lotrimin 2% 3-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day treatment with 200-mg clotrimazole suppositories
Study: 6761087
Drug: 7-day treatment
Normalized name: Gyne-Lotrimin 1% 7-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day treatment with 100-mg clotrimazole suppositories
Study: 6761087
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with miconazole or clotrimazole
Study: 31060740
Drug: Ambrisentan/Tadalafil fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan/Tadalafil fixed-dose combination (10 mg ambrisentan + 40 mg tadalafil)
Study: 31060740
Drug: Ambrisentan/Tadalafil fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan/Tadalafil fixed-dose combination (5 mg/20 mg)
Study: 31060740
Drug: Ambrisentan/Tadalafil fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan/Tadalafil fixed-dose combination (5 mg/40 mg)
Study: 9932217
Drug: 5-day structured
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day structured treatment and teaching programme (DTTP) for intensified insulin therapy
Study: 7829634
Drug: GH (Humatrope,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH (Humatrope, Eli Lilly; 0.074 mg/kg, sc, 3 times/week; n = 9)
Study: 2574986
Drug: Extradural diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural diamorphine 0.1 mg kg‐1
Study: 2574986
Drug: Extradural somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural somatostatin 3 mg
Study: 764996
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of acetone-inactivated and dried typhoid vaccine
Study: 764996
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of acetone-inactivated and dried typhoid vaccine
Study: 21350423
Drug: Cytoflavin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin and basic treatment (trental and group B vitamins)
Study: 21350423
Drug: Corticosteroids (metipred)
Normalized name: Veripred
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (metipred) as an add-on in pulse-treatment regime
Study: 19118069
Drug: Pemetrexed 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 900 mg/m(2) + 75 mg/m(2) cisplatin
Study: 19118069
Drug: Pemetrexed 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 800 mg/m(2) + 75 mg/m(2) cisplatin
Study: 19118069
Drug: Pemetrexed (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (various doses)
Study: 19118069
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m(2) + 75 mg/m(2) cisplatin
Study: 29530257
Drug: Cognitive Preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Preparation + Video Feedback + Audience Feedback + Cognitive Review (CP + VF + AF + CR)
Study: 29530257
Drug: Cognitive Preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Preparation + Video Feedback + Cognitive Review (CP + VF + CR)
Study: 29530257
Drug: Cognitive Preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Preparation + Video Feedback only (CP + VF)
Study: 16241946
Drug: BAY 59-7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59-7939 (2.5 mg b.i.d.)
Study: 16241946
Drug: BAY 59-7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59-7939 (5 mg b.i.d.)
Study: 16241946
Drug: BAY 59-7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59-7939 (10 mg b.i.d.)
Study: 16241946
Drug: BAY 59-7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59-7939 (20 mg b.i.d.)
Study: 16241946
Drug: BAY 59-7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59-7939 (30 mg b.i.d.)